{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:36:40Z","timestamp":1793781400860,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Program of Shanghai Pudong New Area Health Commission","award":["PW2021A-41"],"award-info":[{"award-number":["PW2021A-41"]}]},{"name":"Scientific Research Program of Shanghai Pudong New Area Health Commission","award":["PW2024A-40"],"award-info":[{"award-number":["PW2024A-40"]}]},{"name":"Pudong New Area Science and Technology Development Foundation","award":["PKJ2023-Y42"],"award-info":[{"award-number":["PKJ2023-Y42"]}]},{"DOI":"10.13039\/501100007279","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","award":["20224Y0273"],"award-info":[{"award-number":["20224Y0273"]}],"id":[{"id":"10.13039\/501100007279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The application of carbon ion radiotherapy (CIRT) for unresectable primary or recurrent soft tissue sarcoma (STS) remains controversial and existing data are limited. We herein present our institutional experience with CIRT for unresectable primary or recurrent STS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated the outcomes of CIRT in unresectable primary or recurrent STS patients at our center. We assessed the 4\u2014and 5\u2014year local control (LC), overall survival (OS), distant metastasis free survival (DMFS), progression free survival (PFS), as well as acute and late toxicities. Additionally, we analyzed the prognostic factors associated with the treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between June 2015 and August 2022, 48 consecutive patients with unresectable primary (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098, 16.7%) or recurrent (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940, 83.3%) STS were treated with CIRT. The most common tumor sites were the retroperitoneum and pelvis (75.0%). The predominant histological subtypes included liposarcoma (20.8%), leiomyosarcoma (10.4%), synovial sarcoma (8.3%) and undifferentiated pleomorphic sarcoma (8.3%). Nine patients (18.8%) had a history of prior in-field radiotherapy. The median follow-up duration was 48.6\u00a0months. The 4-year LC, OS, DMFS, and PFS rates were 65.8%, 59.7%, 50.3%, and 36.7%, respectively. The 5-year LC, OS, DMFS, and PFS rates were 60.3%, 54.7%, 44.0%, and 28.0%, respectively. The median survival time was 67.3\u00a0months. Late toxicities included grade 3 dermatitis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092, 4.2%), grade 3 decreased joint range of motion (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091, 2.1%), and grade 3 peripheral neuropathy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091, 2.1%). Patients who received a higher prescribed dose (biologically effective dose, BED\u2009\u2265\u2009129\u00a0Gy) exhibited significantly better LC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010) and PFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) compared to those who received a lower prescribed dose. A pre-CIRT neutrophil-to-lymphocyte ratio (NLR)\u2009\u2265\u20093 was significantly associated with inferior DMFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For select patients with unresectable primary or recurrent STS, CIRT represents a potentially effective and well-tolerated treatment option, though it requires careful evaluation of neural risks\u2014particularly for lesions adjacent to critical nerve structures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16213-w","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:44:04Z","timestamp":1780569844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Carbon ion radiotherapy for unresectable primary or recurrent soft tissue sarcomas: long-term outcomes based on the local effect model"],"prefix":"10.1186","volume":"26","author":[{"given":"Ping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"16213_CR1","first-page":"200","volume":"70","author":"AC Gamboa","year":"2020","unstructured":"Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"16213_CR2","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/1078-0432.CCR-18-2700","volume":"25","author":"CP Raut","year":"2019","unstructured":"Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, et al. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. Clinical Cancer Res. 2019;25(8):2664\u201371.","journal-title":"Clinical Cancer Res"},{"key":"16213_CR3","doi-asserted-by":"crossref","unstructured":"Tinganelli W, Durante M. Carbon Ion Radiobiology. Cancers (Basel). 2020;12(10).","DOI":"10.3390\/cancers12103022"},{"issue":"2","key":"16213_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semradonc.2024.02.003","volume":"34","author":"M Ioakeim-Ioannidou","year":"2024","unstructured":"Ioakeim-Ioannidou M, Rose M, Chen YL, MacDonald SM. The use of proton and carbon ion radiation therapy for sarcomas. Semin Radiat Oncol. 2024;34(2):207\u201317.","journal-title":"Semin Radiat Oncol"},{"issue":"9","key":"16213_CR5","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1002\/cam4.1679","volume":"7","author":"R Imai","year":"2018","unstructured":"Imai R, Kamada T, Araki N. Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. Cancer Med. 2018;7(9):4308\u201314.","journal-title":"Cancer Med"},{"issue":"7","key":"16213_CR6","doi-asserted-by":"publisher","first-page":"e14321","DOI":"10.1002\/acm2.14321","volume":"25","author":"J G\u00f3ra","year":"2024","unstructured":"G\u00f3ra J, Grosshagauer S, Fossati P, Mumot M, Stock M, Schafasand M, et al. The sensitivity of radiobiological models in carbon ion radiotherapy (CIRT) and its consequences on the clinical treatment plan: Differences between LEM and MKM models. J Appl Clin Med Phys. 2024;25(7):e14321.","journal-title":"J Appl Clin Med Phys"},{"key":"16213_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2019.08.022","volume":"141","author":"S Molinelli","year":"2019","unstructured":"Molinelli S, Bonora M, Magro G, Casale S, Dale JE, Fossati P, et al. RBE-weighted dose in carbon ion therapy for ACC patients: Impact of the RBE model translation on treatment outcomes. Radiother Oncol. 2019;141:227\u201333.","journal-title":"Radiother Oncol"},{"key":"16213_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.radonc.2022.08.008","volume":"175","author":"S Grosshagauer","year":"2022","unstructured":"Grosshagauer S, Fossati P, Schafasand M, Carlino A, Poljanc K, Radakovits T, et al. Organs at risk dose constraints in carbon ion radiotherapy at MedAustron: translations between LEM and MKM RBE models and preliminary clinical results. Radiother Oncol. 2022;175:73\u20138.","journal-title":"Radiother Oncol"},{"issue":"1","key":"16213_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJK Guthrie","year":"2013","unstructured":"Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil\u2013lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218\u201330.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"16213_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1667\/RADE-20-00226.1","volume":"196","author":"RL Haas","year":"2021","unstructured":"Haas RL, Floot BGJ, Scholten AN, van der Graaf WTA, van Houdt W, Schrage Y, et al. Cellular radiosensitivity of soft tissue sarcoma. Radiat Res. 2021;196(1):23\u201330.","journal-title":"Radiat Res"},{"key":"16213_CR11","doi-asserted-by":"publisher","first-page":"110644","DOI":"10.1016\/j.radonc.2024.110644","volume":"202","author":"JM Bryant","year":"2025","unstructured":"Bryant JM, Mills MN, Liveringhouse C, Palm R, Druta M, Brohl A, et al. Hypofractionated accelerated radiation dose-painting (HARD) improves outcomes in unresected soft-tissue sarcoma. Radiother Oncol. 2025;202:110644.","journal-title":"Radiother Oncol"},{"key":"16213_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.radonc.2022.05.020","volume":"173","author":"B Allignet","year":"2022","unstructured":"Allignet B, Waissi W, Geets X, Dufresne A, Brahmi M, Ray-Coquard I, et al. Long-term outcomes after definitive radiotherapy with modern techniques for unresectable soft tissue sarcoma. Radiother Oncol. 2022;173:55\u201361.","journal-title":"Radiother Oncol"},{"issue":"4","key":"16213_CR13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.ijrobp.2008.12.019","volume":"75","author":"I Serizawa","year":"2009","unstructured":"Serizawa I, Kagei K, Kamada T, Imai R, Sugahara S, Okada T, et al. Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2009;75(4):1105\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16213_CR14","doi-asserted-by":"crossref","unstructured":"Imai R, Yonemoto T, Araki N, Takiyama H, Ikawa H, Yamada S, et al. Carbon ion radiotherapy for retroperitoneal sarcoma: a single-institution study. Cancers. 2025;17(20).","DOI":"10.3390\/cancers17203395"},{"issue":"3","key":"16213_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ijrobp.2005.03.004","volume":"63","author":"L Kepka","year":"2005","unstructured":"Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005;63(3):852\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"16213_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1080\/0284186X.2022.2066983","volume":"61","author":"B Allignet","year":"2022","unstructured":"Allignet B, Sunyach MP, Geets X, Waissi W. Is there a place for definitive radiotherapy in the treatment of unresectable soft-tissue sarcoma? A systematic review. Acta Oncol. 2022;61(6):720\u20139.","journal-title":"Acta Oncol"},{"issue":"Spec No 1(Spec","key":"16213_CR17","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1259\/bjr\/13783281","volume":"84","author":"R Imai","year":"2011","unstructured":"Imai R, Kamada T, Sugahara S, Tsuji H, Tsujii H. Carbon ion radiotherapy for sacral chordoma. Br J Radiol. 2011;84(Spec No 1(Spec Iss 1)):S48-54.","journal-title":"Br J Radiol"},{"key":"16213_CR18","doi-asserted-by":"crossref","unstructured":"Nachankar A, Schafasand M, Hug E, Martino G, G\u00f3ra J, Carlino A, et al. Sacral-Nerve-Sparing Planning Strategy in Pelvic Sarcomas\/Chordomas Treated with Carbon-Ion Radiotherapy. Cancers. 2024;16(7).","DOI":"10.3390\/cancers16071284"},{"issue":"36","key":"16213_CR19","doi-asserted-by":"publisher","first-page":"e12176","DOI":"10.1097\/MD.0000000000012176","volume":"97","author":"G Liu","year":"2018","unstructured":"Liu G, Ke LC, Sun SR. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: a meta-analysis. Medicine (Baltimore). 2018;97(36):e12176.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"16213_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/1078-0432.CCR-22-2897","volume":"29","author":"M Fiore","year":"2023","unstructured":"Fiore M, Ljevar S, Pasquali S, Morelli D, Callegaro D, Sanfilippo R, et al. Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study. Clin Cancer Res. 2023;29(3):614\u201320.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"16213_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.suronc.2018.07.012","volume":"27","author":"DY Garc\u00eda-Ortega","year":"2018","unstructured":"Garc\u00eda-Ortega DY, \u00c1lvarez-Cano A, S\u00e1nchez-Llamas LA, Caro-Sanchez CHS, Mart\u00ednez-Said H, Luna-Ortiz K, et al. Neutrophil\/lymphocyte ratio is associated with survival in synovial sarcoma. Surg Oncol. 2018;27(3):551\u20135.","journal-title":"Surg Oncol"},{"key":"16213_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.radonc.2022.10.027","volume":"177","author":"A Barcellini","year":"2022","unstructured":"Barcellini A, Fontana G, Filippini DM, Ronchi S, Bonora M, Vischioni B, et al. Exploring the role of neutrophil-to-lymphocyte ratio and blood chemistry in head and neck adenoid cystic carcinomas treated with carbon ion radiotherapy. Radiother Oncol. 2022;177:143\u201351.","journal-title":"Radiother Oncol"},{"key":"16213_CR23","doi-asserted-by":"publisher","first-page":"110239","DOI":"10.1016\/j.radonc.2024.110239","volume":"195","author":"C Martinez","year":"2024","unstructured":"Martinez C, Asso RN, Rastogi N, Freeman CR, Cury FL. Neutrophil-to-lymphocyte ratio for the prediction of soft tissue sarcomas response to pre-operative radiation therapy. Radiother Oncol. 2024;195:110239.","journal-title":"Radiother Oncol"},{"issue":"1","key":"16213_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41420-021-00731-6","volume":"7","author":"H Zhou","year":"2021","unstructured":"Zhou H, Yang P, Li H, Zhang L, Li J, Zhang T, et al. Carbon ion radiotherapy boosts anti-tumour immune responses by inhibiting myeloid-derived suppressor cells in melanoma-bearing mice. Cell death discovery. 2021;7(1):332.","journal-title":"Cell death discovery"},{"key":"16213_CR25","doi-asserted-by":"crossref","unstructured":"Sudo M, Tsutsui H, Fujimoto J. carbon ion irradiation activates anti-cancer immunity. Int J Mol Sci. 2024;25(5).","DOI":"10.3390\/ijms25052830"},{"issue":"12","key":"16213_CR26","doi-asserted-by":"publisher","first-page":"e2550195","DOI":"10.1001\/jamanetworkopen.2025.50195","volume":"8","author":"J Nikitas","year":"2025","unstructured":"Nikitas J, Kendal JK, Savjani RR, Jackson N, Peterson N, Deng J, et al. Five-day preoperative radiation therapy for patients with high-risk soft tissue sarcoma: a nonrandomized clinical trial. JAMA Netw Open. 2025;8(12):e2550195.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"16213_CR27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(22)00638-6","volume":"23","author":"BA Guadagnolo","year":"2022","unstructured":"Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, et al. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2022;23(12):1547\u201357.","journal-title":"Lancet Oncol"},{"issue":"1","key":"16213_CR28","doi-asserted-by":"publisher","first-page":"e35542","DOI":"10.1002\/cncr.35542","volume":"131","author":"AJ Bishop","year":"2025","unstructured":"Bishop AJ, Mitra D, Farooqi A, Swanson DM, Hempel C, Willis T, et al. Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes. Cancer. 2025;131(1):e35542.","journal-title":"Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16213-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16213-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16213-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:02:38Z","timestamp":1786334558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16213-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16213"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16213-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7817850\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Shanghai Proton and Heavy Ion Center (SPHIC), Shanghai, China (Approval No. 260415EXP-01). Informed consent to participate was obtained from all individual participants included in the study. The youngest participant was 16 years old; no participant was under the age of 16, thus consent from parents or legal guardians was not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"959"}}